XML 67 R55.htm IDEA: XBRL DOCUMENT v3.24.3
Share-based compensation - Plans (Details) - $ / shares
9 Months Ended
Jan. 01, 2024
Oct. 02, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Weighted average grant date fair value     $ 11.47 $ 3.67  
Dr. Clay Siegall | Morphimmune Inc | One-year anniversary          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Percentage of vesting   25.00%      
Dr. Clay Siegall | Morphimmune Inc | Over next 36 months          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Vesting period   36 months      
Percentage of vesting   75.00%      
2020 Plan          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Shares available for grant     1,077,406    
Increase in shares available for future issuance 1,730,071        
MorphImmune Plan          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Shares available for grant     940,871    
Employee Stock Purchase Plan          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Shares available for grant     906,251   473,733
Increase in shares available for future issuance 432,518   906,251    
Stock issued during period     0